Topobexin targets the Topoisomerase II ATPase domain for beta isoform-selective inhibition and anthracycline cardioprotection
Jan Kubeš(University Hospital Hradec Králové), Matthew J. Schellenberg(Mayo Clinic), Anna Jirkovská(University Hospital Hradec Králové), Galina Karabanovich(University Hospital Hradec Králové), Taylor L. Witter(Mayo Clinic), Caroline A. Austin(Newcastle University), Iuliia Melnikova(University Hospital Hradec Králové), Veronika Keresteš(University Hospital Hradec Králové), Anh Cong(Mayo Clinic in Arizona), Petra Štěrbová‐Kovaříková(University Hospital Hradec Králové), Tomáš Šimůnek(Charles University), Olga Lenčová(University Hospital Hradec Králové), Jaroslav Roh(Charles University), Martin Štěrba(Charles University), Lenka Applová(University Hospital Hradec Králové), Jasmina Paluncic, Hana Bavlovič Piskáčková, Jiřı́ Kuneš(University Hospital Hradec Králové), Julia R Alvey(Mayo Clinic in Arizona), Lise C. M. Arrouye(Mayo Clinic in Arizona), Petra Kollárová-Brázdová(University Hospital Hradec Králové)
Cited by 14
Related Papers
Human topoisomerases and their roles in genome stability and organization
|Nature Reviews Molecular Cell Biology|2022|446
Role of Serum Biomarkers in Cancer Patients Receiving Cardiotoxic Cancer Therapies: A Position Statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of Cardiology
|European Journal of Heart Failure|2020|344
Deficiency of terminal ADP‐ribose protein glycohydrolase TARG1/C6orf130 in neurodegenerative disease
|The EMBO Journal|2013|309